Spread of nasopharyngeal carcinoma is reduced by bevacizumab, according to phase 2 trial results
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.
Dec 16, 2011
0
0